Teratyde 250 Μg/Ml 250 μg/ml Solution for Injection
PDF Leaflet Revision Date: 22 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of osteoporosis in postmenopausal women and men at risk for fractures.
Dosage (summary)
20 u03bcg once daily by subcutaneous injection.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Digitalis
- Hydrochlorothiazide
- Furosemide
Contraindications
- Hypersensitivity to teriparatide
- Hypercalcaemia
- Severe renal impairment
- Metabolic bone diseases
Common side effects
- Nausea
- Dizziness
- Headache
- Pain in limb
Counselling Points
- Educate on proper injection techniques.
- Use calcium and vitamin D supplements.
- Avoid use in pregnancy and breastfeeding.
Serious warnings
- Risk of osteosarcoma with prolonged use
- Monitor serum calcium levels
Important Disclaimer
The Teratyde 250 Μg/Ml 250 μg/ml Solution for Injection professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
